Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo International has announced that affiliates of the company have completed the acquisition of worldwide rights to Sumavel DosePro (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix for $85m in cash and rights to additional cash payments based on the achievement of certain commercial milestones.
Subscribe to our email newsletter
In addition, Endo will assume an existing third party royalty obligation on net sales. The transaction will be financed with Endo’s current cash on hand.
Sumavel DosePro is a prescription medicine, given with a needle-free delivery system for the acute treatment of migraine, with or without aura, or cluster headaches in adults. In clinical studies, relief started within ten minutes for some patients following self-administration, with most achieving relief within one or two hours.
A burst of air delivers sumatriptan just under the skin in less than a second. Sumavel DosePro is designed to be used in just three simple steps: SNAP, FLIP, PINCH & PRESS. In a study evaluating ease of use, 51 out of 52 people used Sumavel DosePro correctly the first time with little instruction during a migraine attack.